Feature | March 26, 2015

FDA Updates MQSA Facility Certification Extension Requirements for Digital Breast Tomosynthesis Systems

FDA, MQSA, tomosynthesis, DBT, certificate extension, requirements

March 26, 2015 — The U.S. Food and Drug Administration (FDA) released updated requirements for a mammography facility to extend its Mammography Quality Standards Act (MQSA) certification for digital breast tomosynthesis (DBT) systems.

All of the following information must be included with the application:

1: Manufacturers name of FFDM-DBT unit

2. Facility Status Information

a. Facility Name and FDA Facility ID Number
b. FDA Certificate Expiration Date
c. Current Accreditation Body for the 2D unit
d. Accreditation Expiration Date
e. Facility Contact Person for DBT unit
f. Contact Person’s Title
g. Contact Person’s Telephone, Fax, E-mail
h. Facility Address
i. Facility Owner

3. DBT Unit Identification

a. Machine Manufacturer
b. Machine Model
c. Year of Manufacture
d. Serial Number
e. Accreditation Body Unit Number

4. DBT Digital Image Receptor Identification (if interchangeable)

a. Receptor Manufacturer
b. Receptor Model
c. Year of Manufacture
d. Serial Number (if applicable)

5. Identification of Printer for Hard Copy Interpretation (mandatory even for facilities performing only soft copy interpretation)

a. Printer Manufacturer
b. Printer Model
c. Year of Manufacture
d. Serial Number

6. Final Interpretation Review Monitor Identification (if soft copy display is available)

a. Monitor Manufacturer
b. Monitor Model
c. Year of Manufacture
d. Serial Number

7. Phantom Identification

a. Phantom Manufacturer
b. Phantom Model

8. Hardcopy phantom image (3D mode) must be included when submitting application.

9. Personnel Qualifications

a. Interpreting Physicians who are qualified to interpret DBT mammograms (see Qualified Personnel)
b. Radiological Technologists who are qualified to perform DBT mammography examinations and the manufacturer recommended quality assurance tests (see Qualified Personnel)
c. Medical Physicists who are qualified to perform equipment evaluations and/or surveys of DBT mammography units (Qualified Personnel)

10. Complete Detailed report of Mammography Equipment Evaluation (MEE) (must have been conducted in accordance with 900.12(e)(10) within the 6 months prior to the request for use approval) must be included when submitting application.

a. Statement that equipment performance, as required under the following sections of the
MQSA final regulation 21 CFR 900.12(b), is met:

(1) Prohibited Equipment
(2) Specifically Designed for Mammography
(3) Motion of Tube-Image Receptor Assembly
(4)(iii) Removable Grid (if applicable to the DBT system used) (5) Beam Limitation and Light Fields
(6) Magnification
(7) Focal Spot Selection
(8) Compression
(9) Technique Factor Selection and Display
(10) Automatic Exposure Control

b. The results of quality control tests as required under the following sections of the
MQSA final regulations 21CFR 900.12(e):

(4)(iii) Compression Device Performance
(5)(i) Automatic Exposure Control Performance (if applicable to the DBT system used) (5)(ii) Kilovoltage Peak Accuracy and Reproducibility
(5)(iii) Focal Spot Condition (Resolution) (5)(iv) Beam Quality and Half-Value Layer
(5)(v) Breast Entrance Air Kerma and AEC Reproducibility (if applicable to the DBT
system used) (5)(vi) Dosimetry
(5)(vii) X-Ray Field/Light field/Image receptor/Compression paddle alignment
(5)(ix) System Artifacts
(5)(x) Radiation Output
(5)(xi) Decompression (or alternative standards allowed for these requirements) (6) Quality Control Tests – Other Modalities (Facilities must perform all DBT manufacturer recommended quality control tests including the medical physicist’s tests for Soft Copy Display system)

c. The results of the phantom image quality tests, including a sample image
d. If any of the requirements in 8 a, b, or c are not met, submit documentation of successful corrective action
e. If any of the requirements in 8 a or b are not performed, explain why the requirement is not applicable
f. Date of the MEE
g. Name and address of the physicist(s) who performed the MEE

11. DBT Manufacturer’s Quality Control Program

a. Name of the Quality Control Manual
b. Year published
c. Revision number, if not the original
d. Printing number, if not the original

12. Signature of facility contact person for the DBT unit

 

Note 1: Under MQSA, each manufacturer’s Digital Breast Tomosynthesis system is currently considered a separate new mammographic modality, and the personnel requirements for new modality training apply.

Note 2: In order to use the tomosynthesis portion of the unit, the facility must apply to FDA to have its certificate extended to include that portion of the unit. The certification extension only applies to the DBT portion of the unit. The facility must have the 2-D portion of the unit accredited by one of the accreditation bodies already approved to accredit the 2-D portion.

For more information: www.fda.gov

Related Content

Mammograms of a 49-year-old woman with invasive lobular carcinoma on the right-side breast

Mammograms of a 49-year-old woman with invasive lobular carcinoma on the right-side breast. A small mass with micro-calcifications on the right-side breast was detected correctly by AI with an abnormality score of 96%. This case was recalled by 7 out of 14 radiologists (4 breast radiologists and 3 general radiologists) initially (without AI) and all 14 radiologists recalled this case correctly with the assistance of AI.

News | Artificial Intelligence | February 11, 2020
February 11, 2020 — A new study, published in...
Sponsored Content | Videos | Mammography | January 24, 2020
Imaging Technology News Contributing Editor Greg Freiherr interviewed...
Videos | MRI Breast | December 26, 2019
Gillian Newstead, M.D., director of global breast imaging and former professor at the University of Chicago, explains
A new market report focuses on breast imaging devices, paying special attention to their recent emergence

Image courtesy of Eizo

News | Breast Imaging | December 17, 2019
December 17, 2019 — The ...
Researchers recently conducted the largest population-based long-term retrospective analysis of non-cancer causes of death among patients with breast cancer

Image courtesy of RSNA

News | Clinical Trials | December 17, 2019
December 16, 2019 — Survival rates for patients with breast cancer have improved significantly in the last four decad
#RSNA19 GE Healthcare introduced Serena Bright, the healthcare industry’s first contrast-enhanced mammography solution for biopsy
News | Mammography | November 30, 2019
November 30, 2019 — To help empower clinicians and patients in their fight against...
This bar graph shows breast cancer presentation by screening interval #RSNA19

This bar graph shows breast cancer presentation by screening interval. Image courtesy of study author and RSNA

News | Breast Imaging | November 28, 2019
November 28, 2019 — Cancers found in patients undergoing annual...
News | Breast Imaging | November 26, 2019
November 26, 2019 — Unifi Workspace, a new comprehensive breast diagnostic reading solution from Hologic, will launch